Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Diabetes

Free Subscription Articles published in Kidney Int Retrieve available abstracts of 49 articles: HTML format

Single Articles

May 2026
1. LV Z, Hu J, Lang Y, Fan X, et al
   Role of the Post-translational ISGylation of Interferon Regulatory Factor 9 in Diabetes-Induced Podocyte Injury.
   Kidney Int. 2026 May 22:S0085-2538(26)00400-X. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   
2. VAN HEUGTEN MH, Beckmann SB, Salib M, Curovic VR, et al
   Distinct proteomic signatures of urinary extracellular vesicles link to albuminuria and treatment responses in diabetic kidney disease.
   Kidney Int. 2026 May 21:S0085-2538(26)00396-0. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   April 2026
3. FERREIRA RM, Gisch DL, Phillips CL, Cheng YH, et al
   A MEF2C transcription factor network regulates proliferation of glomerular endothelial cells in diabetic kidney disease.
   Kidney Int. 2026 Apr 27:S0085-2538(26)00310-8. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   
4. QI Z, Tang Y, Croy JE, Wilson JM, et al
   Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody.
   Kidney Int. 2026 Apr 24:S0085-2538(26)00306-6. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   
5. CAZA TN, Charu V, Dai DF, Davis VG, et al
   Clinical and Histologic Predictors of Non-Diabetic Kidney Disease in Patients with Diabetes Mellitus.
   Kidney Int. 2026 Apr 23:S0085-2538(26)00305-4. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   March 2026
6. CHERNEY DZI, Bonefeld K, Crater G, Dwyer JP, et al
   A double-blind, randomized, placebo-controlled, phase 2 trial examined the efficacy and safety of monlunabant in adults with diabetic kidney disease.
   Kidney Int. 2026 Mar 20:S0085-2538(26)00217-6. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   
7. WAN F, Yang B, Li J, Lin L, et al
   Proteinase 3 Drives Murine Diabetic Kidney Disease by Mediating Caspase-3-dependent Apoptosis of Podocytes.
   Kidney Int. 2026 Mar 13:S0085-2538(26)00163-8. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   February 2026
8. GESUALDO L, Kretzler M, Pontrelli P
   Deep endotyping of renal damage in type 2 diabetes: ex uno, plures.
   Kidney Int. 2026 Feb 27:S0085-2538(26)00143-2. doi: 10.1016/j.kint.2026.
   PubMed     Abstract available
   
   
   January 2026
9. PATEL HA, Wang J, Zinn CJ, Learmonth M, et al
   Targeting Cellular Senescence in Diabetic Kidney Disease: Potential of Regenerative, Cell-based Therapies and Other Senotherapeutic Approaches.
   Kidney Int. 2026 Jan 23:S0085-2538(26)00054-2. doi: 10.1016/j.kint.2025.
   PubMed     Abstract available
   
   
   
10. SCHUG AP, Ly LT, Eckardt KU, Balzer MS, et al
    The Case | The sweet twirl-chorea as a diabetic complication: an elderly patient with CKD, hyperglycemia, and chorea.
    Kidney Int. 2026;109:235-236.
    PubMed    
    
    
    
11. PRUIJM M, Belmar N, Bjornstad P, Cherney DZI, et al
    REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
    Kidney Int. 2026;109:6-16.
    PubMed     Abstract available
    
    
    November 2025
12. WANG YH, Chang DY, Zhao YY, Chi-Wai Tang S, et al
    Mitochondrial protein TOMM7 alleviates diabetic kidney disease by regulating mitophagy via intracellular redistribution of phospholipase PLA2G6.
    Kidney Int. 2025 Nov 21:S0085-2538(25)00882-8. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
13. NARONGKIATIKHUN P, Bjornstad P
    Unmasking the hidden burden of prediabetes on kidney function.
    Kidney Int. 2025;108:751-753.
    PubMed     Abstract available
    
    
    
14. MELSOM T, Brobak KM, Norvik JV, Enoksen IT, et al
    Iohexol clearance, but not estimated GFR, reveals a steeper GFR decline in patients with prediabetes.
    Kidney Int. 2025;108:938-947.
    PubMed     Abstract available
    
    
    October 2025
15. LI X, He JC, Lee K
    New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease.
    Kidney Int. 2025 Oct 23:S0085-2538(25)00838-5. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
16. NAJAFIAN B, Caramori ML, Vestra MD, Saller A, et al
    Heterogeneity in the relationships between albuminuria and glomerular structure in type 1 and type 2 diabetes.
    Kidney Int. 2025 Oct 6:S0085-2538(25)00771-9. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    August 2025
17. YANG R, Hou Q, Chen R, Ma Z, et al
    Protein UHRF1-mediated dual dysregulation of molecular chaperone GRP78 induces endoplasmic reticulum stress and aggravates diabetic nephropathy.
    Kidney Int. 2025 Aug 25:S0085-2538(25)00654-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
18. BANSAL A, Chonchol M
    Metabolic dysfunction-associated kidney disease: pathogenesis and clinical manifestations.
    Kidney Int. 2025;108:194-200.
    PubMed     Abstract available
    
    
    July 2025
19. NAVANEETHAN SD, Anker SD, Filippatos G, Pitt B, et al
    Efficacy and safety of finerenone in patients with an acute change in estimated glomerular filtration rate in the prespecified FIDELITY pool analysis.
    Kidney Int. 2025;108:136-144.
    PubMed     Abstract available
    
    
    
20. IMAMURA M, Kadowaki T, Maeda S
    Genetic studies on metabolic disorder-associated kidney diseases.
    Kidney Int. 2025;108:30-37.
    PubMed     Abstract available
    
    
    June 2025
21. BAVANANDAN S, Noronha IL, Tchokhonelidze I, Liew A, et al
    Metabolic disorder associated kidney disease and diabetic kidney disease in developing countries.
    Kidney Int. 2025 Jun 27:S0085-2538(25)00493-4. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
22. ORTIZ A, Arreola Guerra JM, Chan JCN, Jha V, et al
    Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2025 Jun 18:S0085-2538(25)00334-5. doi: 10.1016/j.kint.2025.
    PubMed     Abstract available
    
    
    
23. VAN LOON E, Gillard P, Naesens M
    SGLT2 inhibitors fulfill their expectations in diabetic kidney transplant recipients.
    Kidney Int. 2025;107:966-969.
    PubMed    
    
    
    May 2025
24. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary.
    Kidney Int. 2025;107:767-771.
    PubMed    
    
    
    April 2025
25. LI L, Liu Y
    Podocyte aging and diabetic kidney disease.
    Kidney Int. 2025;107:596-598.
    PubMed     Abstract available
    
    
    January 2025
26. LI Y, Duan Y, Chu Q, Lv H, et al
    G-protein coupled receptor GPR124 protects against podocyte senescence and injury in diabetic kidney disease.
    Kidney Int. 2025 Jan 17:S0085-2538(25)00057-2. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    December 2024
27. MIMURA I, Chen Z, Natarajan R
    Epigenetic alterations and memory: key players in the development/progression of chronic kidney disease promoted by acute kidney injury and diabetes.
    Kidney Int. 2024 Dec 24:S0085-2538(24)00918-9. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
28. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
    Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
    Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
29. KRISHNAN S, Manoharan J, Wang H, Gupta D, et al
    Corrigendum to "CD248 induces a maladaptive unfolded protein response in diabetic kidney disease." Kidney International 2023;103:304-319.
    Kidney Int. 2024;106:1193-1196.
    PubMed    
    
    
    November 2024
30. LV Z, Hu J, Su H, Yu Q, et al
    TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00800-7. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
31. MIYAMOTO S, Heerspink HJL, de Zeeuw D, Sakamoto K, et al
    A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope.
    Kidney Int. 2024;106:972-984.
    PubMed     Abstract available
    
    
    September 2024
32. NARONGKIATIKHUN P, Bjornstad P
    Deciphering the kidney hemodynamic effects of SGLT2 inhibition: translating insights from rats to humans in type 2 diabetes.
    Kidney Int. 2024;106:354-356.
    PubMed     Abstract available
    
    
    
33. VIVARELLI M, Barratt J, Beck LH Jr, Fakhouri F, et al
    The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
    Kidney Int. 2024;106:369-391.
    PubMed     Abstract available
    
    
    August 2024
34. SELVARAJAH V, Robertson D, Hansen L, Jermutus L, et al
    A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.
    Kidney Int. 2024 Aug 30:S0085-2538(24)00629-X. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    July 2024
35. HEROLD JM, Wiegrebe S, Nano J, Jung B, et al
    Population-based reference values for kidney function and kidney function decline in 25- to 95-year-old Germans without and with diabetes.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00528-3. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
36. DRUEKE TB, Massy ZA
    Unexpected metabolic effects of sodium-glucose cotransporter 2 inhibitors.
    Kidney Int. 2024;106:12-15.
    PubMed    
    
    
    
37. FENG Y, Sun Z, Fu J, Zhong F, et al
    Podocyte-derived soluble RARRES1 drives kidney disease progression through direct podocyte and proximal tubular injury.
    Kidney Int. 2024;106:50-66.
    PubMed     Abstract available
    
    
    June 2024
38. NANGAKU M
    SGLT2 inhibitor: 2-way superstar in nephrology?
    Kidney Int. 2024;105:1176-1177.
    PubMed    
    
    
    
39. KUME S, Packer M
    SGLT2 inhibitors act as metabolic transducers to restore healthy nutrient deprivation and surplus signaling in the kidney.
    Kidney Int. 2024;105:1172-1176.
    PubMed    
    
    
    
40. YAU K, Cherney DZI, van Raalte DH, Wever BE, et al
    Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect.
    Kidney Int. 2024;105:1168-1172.
    PubMed    
    
    
    
41. MCEVOY CM, Yuen DA
    Not too much, not too little-just the right amount: the story of YAP in the podocyte.
    Kidney Int. 2024;105:1157-1159.
    PubMed     Abstract available
    
    
    May 2024
42. WADA Y, Kidokoro K, Kondo M, Tokuyama A, et al
    Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.
    Kidney Int. 2024 May 25:S0085-2538(24)00340-5. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    
43. HONG YA, Nangaku M
    Endogenous adenine as a key player in diabetic kidney disease progression: an integrated multiomics approach.
    Kidney Int. 2024;105:918-920.
    PubMed    
    
    
    
44. WANG L, Tian H, Wang H, Mao X, et al
    Disrupting circadian control of autophagy induces podocyte injury and proteinuria.
    Kidney Int. 2024;105:1020-1034.
    PubMed     Abstract available
    
    
    April 2024
45. MURPHY DP, Wolfson J, Reule S, Johansen KL, et al
    A cohort study of sodium-glucose cotransporter-2 inhibitors after acute kidney injury among Veterans with diabetic kidney disease.
    Kidney Int. 2024 Apr 27:S0085-2538(24)00309-0. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    
    March 2024
46. NEGRI AL
    Sodium-glucose cotransporter 2 inhibitors in the treatment of refractory hypomagnesemia.
    Kidney Int. 2024;105:638.
    PubMed    
    
    
    
47. SHAH CV
    Sodium-glucose cotransporter 2 inhibition, epidermal growth factor, and magnesium homeostasis: is there a link?
    Kidney Int. 2024;105:638-639.
    PubMed    
    
    
    
48. CHEN JJ, Lee TH, Yang HY
    Exploring nontraditional cardiorenal advantages of SGLT-2 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2024;105:442-444.
    PubMed     Abstract available
    
    
    February 2024
49. CHEN J, Wang X, He Q, Yang HC, et al
    Inhibition of transcriptional coactivator YAP Impairs the expression and function of transcription factor WT1 in diabetic podocyte injury.
    Kidney Int. 2024 Feb 27:S0085-2538(24)00160-1. doi: 10.1016/j.kint.2024.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum